Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 16/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 2/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL476766 | 0.82 | NR3C1 (0.66) | NR3C1PGRCYP3A4CYP2C9 | |
| SCHEMBL4400814 | 0.82 | NR3C1 (0.54) | NR3C1PGRCYP3A4CYP2C9TRPV1 | |
| SCHEMBL4396953 | 0.80 | NR3C1 (0.49) | NR3C1 | |
| SCHEMBL476735 | 0.76 | NR3C1 (0.68) | NR3C1PGRCYP3A4CYP2C9 | |
| SCHEMBL12663027 | 0.74 | NR3C1 (0.56) | NR3C1PGRCYP3A4CYP2C9TRPV1 | |
| SCHEMBL476762 | 0.74 | NR3C1 (0.67) | NR3C1 | |
| SCHEMBL12663246 | 0.73 | NR3C1 (0.54) | NR3C1CCR1 | |
| SCHEMBL4106128 | 0.73 | NR3C1 (0.54) | NR3C1PGRCYP3A4CYP2C9TRPV1 | |
| SCHEMBL4404083 | 0.73 | NR3C1 (0.41) | NR3C1CYP3A4CYP2C9CCR1CYP17A1 | |
| SCHEMBL4390639 | 0.72 | NR3C1 (0.50) | NR3C1CCR1CYP17A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081910-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008043789-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |